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Assays of 5-hydroxytryptophan 
We modified the analysis method described in our previous study [1] to achieve a better 
separation of 5-hydroxytryptophan (5-HTP) from other co-eluting metabolites. In brief, we 
changed the mobile phase A to ammonium formate buffer (26.9 mmol of ammonium formate 
dissolved in 1 L of ultrapure water, adjusting the pH to ≈3.7 with 874.5 µL [23.1 mmol] of 
formic acid). The gradient setting is shown in Table 1. The column temperature was changed 
to 32°C. Injection volume was increased to 30 µL. Although this modification improved the 
separation of 5-HTP, the resolution of the peak of 5-hydroxyindoleacetic acid became worse 
in a few samples. Therefore, we used this modified method only to measure 5-HTP. 
 
Table 1. Gradient settings for 5-HTP assay 












Initial 1.0 100.0 0.0 0.0  
5.5 1.0 100.0 0.0 0.0 Linear 
12.5 1.0 80.0 20.0 0.0 Linear 
13.0 1.0 0.0 80.0 20.0 Step 
17.0 1.0 100.0 0.0 0.0 Step 
25.0 1.0 100.0 0.0 0.0 Linear 
 
Assays of α-aminoadipic semialdehyde and pipecolic acid 
Standard solutions 
To prepare a standard solution of α-aminoadipic semialdehyde (AASA), we followed the 
method of Sadilkova et al. [2] to obtain 4 mmol/L AASA solution. Strictly speaking, this is a 
mixture of AASA and δ1-piperideine-6-carboxylate, which are in equilibrium at a total 
concentration of 4 mmol/L. We diluted this solution with ultrapure water to 10 µmol/L to be 
used as a calibrator. We also prepared a 10 µmol/L solution of pipecolic acid in ultrapure 
water as a calibrator. Additionally, we prepared quality control samples at 1 µmol/L by 
dilution with ultrapure water. These calibrators and quality controls of AASA and pipecolic 
acid were stored at –80°C. We made mixed amino acid solutions at 10 µmol/L, which were 
used to confirm that the peaks of AASA and pipecolic acid were clearly separated from those 
of other amino acids. 
 
Sample preparation 
Cerebrospinal fluid (CSF) samples (50 µL) with no dilution, serum samples diluted twofold 
by ultrapure water (100 µL), and standard solutions (50 µL) were added with an equivalent 
volume of acetonitrile for deproteinization. After centrifugation at 16,000 × g at 4°C for 10 
min, 50 µL of the supernatant was transferred to another microtube. 
 
For the AASA assay, 25 µL of 0.4 mol/L borate buffer (pH 9.0) was added. Subsequently, 25 
µL of derivatization agent (20 mmol/L of 9-fluorenylmethyl chloroformate [FMOC-Cl] 
dissolved in acetonitrile) was added. After 5 min, the reaction was stopped by the addition of 
50 µL of 100 mmol/L amantadine dissolved in a mixture of 0.02 mol/L HCl and acetonitrile 
[1:1, v/v]. After 3 min, the samples were filtered through 0.45 µm Millex LH filters (Merck 
Millipore, Billerica, MA, USA). 
 
For the assay of pipecolic acid, primary amines were first derivatized by adding 25 µL of 
derivatization agent (75 mmol/L o-phthalaldehyde and 75 mmol/L dithiothreitol dissolved in a 
mixture of 0.4 mol/L borate buffer and acetonitrile [9:1, v/v]). After 3 min, the remaining 
secondary amines, including pipecolic acid, were derivatized by adding 25 µL of 
derivatization agent (20 mmol/L FMOC-Cl dissolved in acetonitrile). After 3 min, the samples 
were filtered through 0.45 µm Millex LH filters. 
 
Chromatographic setting 
The chromatographic system consisted of a Waters Alliance 2695 module with a Waters 2475 
multi λ fluorescence detector (Waters Japan, Tokyo, Japan). 
 
For the AASA assay, the mobile phase A (pH ≈ 7.0) was generated by dissolving 5.082 g (35.8 
mmol) of disodium hydrogen phosphate and 2.904 g (24.2 mmol) of sodium dihydrogen 
phosphate in 1 L of ultrapure water. The mobile phase B was 100% acetonitrile. The mobile 
phase C was ultrapure water. The gradient setting is shown in Table 2. The separation was 
performed through a CORTECS C18 column (2.7 µm, 3.0 mm × 150 mm, Waters) with a 
CORTECS C18 VanGuard cartridge (2.7 µm, 2.1 mm × 5 mm, Waters) at 35°C. The entire 
analysis time was 40 min. 
 
Table 2. Gradient settings for AASA assay 












Initial 0.5 76.0 24.0 0.0  
14.0 0.5 76.0 24.0 0.0 Linear 
14.1 0.5 0.0 60.0 40.0 Step 
15.0 0.5 0.0 80.0 20.0 Step 
16.0 0.5 0.0 24.0 76.0 Step 
17.0 0.5 76.0 24.0 0.0 Step 
40.0 0.5 76.0 24.0 0.0 Linear 
 
For the pipecolic acid assay, the mobile phase A (pH ≈ 7.2) was generated by dissolving 6.019 
g (42.4 mmol) of disodium hydrogen phosphate and 2.112 g (17.6 mmol) of sodium 
dihydrogen phosphate in 1 L of ultrapure water. The mobile phase B was 100% acetonitrile. 
The mobile phase C was ultrapure water. The gradient setting is shown in Table 3. The 
separation was performed through an XBridge BEH C18 XP column (2.5 µm, 3.0 mm × 50 
mm, Waters) with an XBridge BEH C18 XP VanGuard cartridge (2.5 µm, 2.1 mm × 5 mm, 
Waters) at 32°C. The entire analysis time was 15 min. 
 
Table 3. Gradient settings for pipecolic acid assay 












Initial 0.5 74.0 26.0 0.0  
7.0 0.5 74.0 26.0 0.0 Linear 
7.1 0.8 0.0 60.0 40.0 Step 
10.0 0.8 0.0 26.0 74.0 Step 
11.0 0.8 74.0 26.0 0.0 Step 
15.0 0.8 74.0 26.0 0.0 Linear 
 
For both assays, fluorescence detection was performed with excitation at 254 nm and 
emission at 313 nm. Concentration was determined by the heights of the peaks. The samples 
were cooled to 4°C in the autosampler, and the injection volume was 5 µL. At the beginning 
of each analysis run, the concentration of a quality control sample was measured and was 
required to have a relative error (RE) within 15% (0.85 to 1.15 µmol/L). 
 
Validation of the assays 
The linearity of the calibration curve was assessed using Pearson’s correlation coefficient. 
The limit of detection (LOD) was determined based on a signal-to-noise (S/N) ratio ≥ 3. The 
limit of quantification (LOQ) was determined based on an S/N ratio ≥ 10 and RE within 20%. 
Recovery was evaluated by spiking five serum samples by 1 µmol/L and 5 µmol/L. 
 
Results of validation 
The retention time of FMOC-AASA was 15.0 min. We did not observe other extra peaks 
compared with blank samples with the same derivatization process. We checked the identity 
of the FMOC-AASA peak by obtaining the fraction of this peak and flow-injection mass 
spectrometry (negative mode, m/z 366.13). The LOD was below 0.01 µmol/L and the LOQ 
was 0.05 µmol/L (RE –6.0% to +14.0%, n = 5). The calibration curve was linear (r > 0.999) in 
the range of 0.01 to 10 µmol/L, and the intercept was not significantly different from zero. 
Therefore, we chose to use a single-point calibrator at 10 µmol/L. The peak of FMOC-AASA 
was clearly separated from those of other amino acids, and its height did not show a reduction 
after 24 h. The recoveries calculated from five serum samples were 84.6 to 98.8% (mean, 
93.1%) for samples spiked by 1 µmol/L, and 88.6 to 99.7% (mean, 93.5%) for samples spiked 
by 5 µmol/L. The intra-day coefficient of variation (CV) for the quality control samples was 
0.7% (n = 5), and the inter-day CV was 1.6% (n = 5). Example chromatograms are presented 
in Figure 1. 
 
The retention time of pipecolic acid was 6 min. The LOD was 0.02 µmol/L and the LOQ was 
0.05 µmol/L. The calibration curve was linear (r > 0.999) in the range of 0.01 to 10 µmol/L, 
and the intercept was not significantly different from zero. Therefore, we chose to use a 
single-point calibrator at 10 µmol/L. The peak of pipecolic acid was clearly separated from 
those of other amino acids, and its height did not show a reduction after 24 h. The recoveries 
calculated from five serum samples were 92.8 to 126.6% (mean, 111.4%) for samples spiked 
by 1 µmol/L, and 88.5 to 106.0% (mean, 99.8%) for samples spiked by 5 µmol/L. Intra-day 
CV for the quality control samples was 1.2% (n = 5) and inter-day CV was 2.7% (n = 5). 
Example chromatograms are demonstrated in Figure 1. 
 
Reference values are demonstrated in Table 4. They are comparable to previous reports [3,4]. 
 
Table 4. Reference values for AASA and pipecolic acid 
Age 
Serum (µmol/L) CSF (µmol/L) 
AASA Pipecolic acid AASA Pipecolic acid 
0–12 months <0.3 
n = 60 
0.4–5.4 
n = 75 
<0.1 
n = 91 
<0.4 
n = 139 
≥ 1 year <0.3 
n = 30 
0.4–2.8 
n = 26 
<0.1 
n = 38 
<0.1 
n = 30 
 
 
Figure 1. Example chromatograms of the assays for AASA and pipecolic acid 
Panel A: AASA assay for a serum sample from a heathy adult. AASA was not detected. Panel 
B: AASA assay for the same serum sample spiked with 5 µmol/L AASA. AASA was detected 
at 15.0 min. Panel C: Pipecolic acid assay for the same serum sample with no spiking. 
Pipecolic acid was detected at 6.0 min. Panel D: Pipecolic acid assay for the same serum 





[1] Akiyama T, HayashiI Y, Hanaoka Y, et al. Simultaneous measurement of monoamine 
metabolites and 5-methyltetrahydrofolate in the cerebrospinal fluid of children. Clin 
Chim Acta 2017;465:5-10 
[2] Sadilkova K, Gospe SM Jr, Hahn SH. Simultaneous determination of alpha-aminoadipic 
semialdehyde, piperideine-6-carboxylate and pipecolic acid by LC-MS/MS for 
pyridoxine-dependent seizures and folinic acid-responsive seizures. J Neurosci Methods 
2009;184:136-41. 
[3] Plecko B, Stockler-Ipsiroglu S, Paschke E, et al. Pipecolic acid elevation in plasma and 
cerebrospinal fluid of two patients with pyridoxine-dependent epilepsy. Ann Neurol 
2000;48:121-5. 
[4] Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with 
pyridoxine-dependent seizures. Nat Med 2006;12:307-9. 
